 | Up a level |
Group by: Item Type | Date
Jump to: Article | Book Section
Number of items: 4.
Article
- Patterson, L. H., McKeown, S. R., Robson, T., Gallagher, R., Raleigh, S. M. and Orr, S. (1999) Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design. 14(6), pp. 473-486. 0266-9536.
- Raleigh, S. M., Wanogho, E., Burke, M. D. and Patterson, L. H. (1999) Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica. 29(11), pp. 1115-1122. 0049-8254.
- Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R. and Patterson, L. H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. International Journal of Radiation Oncology, Biology, Physics. 42(4), pp. 763-767. 0360-3016.
Book Section
- Patterson, L. H. and Raleigh, S. M. (1998) Reductive metabolism: its application in prodrug activation. In: Gooderham, N. J. (ed.) Drug Metabolism: Towards the Next Millenium. Amsterdam: IOS Press. pp. 72-80.